UB Paderborn / Katalog / Suche / in CDI

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.38-14, Article 38

2019

Link zum Volltext

Verfügbarkeit prüfen

Assessing Similarity Among Individual Tumor Size Lesion Dynamics: The CICIL Methodology

CPT: pharmacometrics and systems pharmacology, 2018-04, Vol.7 (4), p.228-236

2018

Link zum Volltext

Verfügbarkeit prüfen

The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib

Blood, 2011-05, Vol.117 (18), p.4999-5008

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy (RT) in patients (pts) with stage IV NSCLC with disease control after 1st-line chemotherapy or during therapy with an EGFR-TKI: results of an interim analysis

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e20627-e20627

2016

Link zum Volltext

Verfügbarkeit prüfen

Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway

Kidney international, 2001-07, Vol.60 (1), p.83-86

2001

Link zum Volltext

Verfügbarkeit prüfen

Flow Cytometric Measurement of Platelet-Leukocyte Aggregates: A Possible Target to Monitor Platelet Function?

Seminars in thrombosis and hemostasis, 2005-08, Vol.31 (4), p.400-403

2005

Link zum Volltext

Verfügbarkeit prüfen

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time

Thrombosis and haemostasis, 2004-06, Vol.91 (6), p.1137

2004

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT217-CT217

2021

Link zum Volltext

Verfügbarkeit prüfen

Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor

The Journal of pharmacology and experimental therapeutics, 2002-03, Vol.300 (3), p.952

2002

Link zum Volltext

Verfügbarkeit prüfen

Flow Cytometric Measurement of Platelet-Leukocyte Aggregates: A Possible Target to Monitor Platelet Function?

Seminars in thrombosis and hemostasis, 2005-08, Vol.31 (4), p.400-403

2005

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4522: Potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4522-4522

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-021: Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-021-LB-021

2019

Link zum Volltext

Verfügbarkeit prüfen

Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: Pharmacokinetic and pharmacodynamic considerations

Clinical pharmacokinetics, 2004, Vol.43 (14), p.963-981

2004

Link zum Volltext

Verfügbarkeit prüfen

Anticoagulation With Argatroban for Elective Percutaneous Coronary Intervention: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationship of Coagulation Parameters

Journal of clinical pharmacology, 2011-06, Vol.51 (6), p.805-818

2011

Link zum Volltext

Verfügbarkeit prüfen

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease

Clinical pharmacology and therapeutics, 2003-03, Vol.73 (3), p.232-241

2003

Link zum Volltext

Verfügbarkeit prüfen

Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3505-3505

2014

Link zum Volltext

Verfügbarkeit prüfen

Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model

Clinical pharmacology and therapeutics, 2002-03, Vol.71 (3), p.176-185

2002

Link zum Volltext

Verfügbarkeit prüfen

A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants

Biomicrofluidics, 2013-09, Vol.7 (5), p.56502-56502

2013

Link zum Volltext

Verfügbarkeit prüfen

408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A248-A248

2020

Link zum Volltext

Verfügbarkeit prüfen

The integrin antagonist, cilengitide, is a weak inhibitor of αIIbβ3 mediated platelet activation and inhibits platelet adhesion under flow

Platelets (Edinburgh), 2015-02, Vol.26 (1), p.59-66

2015

Link zum Volltext

Verfügbarkeit prüfen

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1333-S1334

2017

Link zum Volltext

Verfügbarkeit prüfen

Using ImageJ for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions

Platelets (Edinburgh), 2010, Vol.21 (1), p.60-66

2010

Link zum Volltext

Verfügbarkeit prüfen

Flow cytometric measurement of platelet- leukocyte aggregates : A possible target to monitor platelet function?: Reliability of platelet function tests and drug monitoring

Seminars in thrombosis and hemostasis, 2005, Vol.31 (4), p.400-403

2005

Link zum Volltext

Verfügbarkeit prüfen

Platelet–leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors

Journal of antimicrobial chemotherapy, 2008-11, Vol.62 (5), p.1118-1121

2008

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Assessing Similarity Among Individual Tumor Size Lesion Dynamics: The CICIL Methodology

The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib

Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy (RT) in patients (pts) with stage IV NSCLC with disease control after 1st-line chemotherapy or during therapy with an EGFR-TKI: results of an interim analysis

Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway

Flow Cytometric Measurement of Platelet-Leukocyte Aggregates: A Possible Target to Monitor Platelet Function?

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time

Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors

Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor

Flow Cytometric Measurement of Platelet-Leukocyte Aggregates: A Possible Target to Monitor Platelet Function?

Abstract 4522: Potent induction of a tumor-specific immune response by a cyclic dinucleotide STING agonist

Abstract LB-021: Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors

Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: Pharmacokinetic and pharmacodynamic considerations

Anticoagulation With Argatroban for Elective Percutaneous Coronary Intervention: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationship of Coagulation Parameters

Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease

Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab

Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model

A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants

408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors

The integrin antagonist, cilengitide, is a weak inhibitor of αIIbβ3 mediated platelet activation and inhibits platelet adhesion under flow

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC

P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC: Topic: IT Clinical

Using ImageJ for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions

Flow cytometric measurement of platelet- leukocyte aggregates : A possible target to monitor platelet function?: Reliability of platelet function tests and drug monitoring

Platelet–leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors

Suchergebnisse filtern